Advocacy intelligence hub — real-time data for patient organizations
ATryn: FDA approved
Prevention of peri-operative and peri-partum thromboembolic events, in hereditary antithrombin deficient patients.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
ATryn
GTC Biotherapeutics, Inc.
ATryn
(recombinant human antithrombin)Orphan drugGTC Biotherapeutics, Inc.